【佳学基因检测】与甲状腺癌相关的肿瘤抑制基因的甲基化

品牌基因检测价格表还有吗

比较肿瘤的基因组学特征与治疗方案设计做了备注《Cancer Biomark》在. 2019;25(1):53-65.发表了一篇题目为《与甲状腺癌相关的肿瘤抑制基因的甲基化》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Anca Botezatu, Iulia V Iancu, Adriana Plesa, Dana Manda, Oana Popa, Marinela Bostan, Mirela Mihaila, Adrian Albulescu, Alina Fudulu, Susana V Vladoiu, Irina Huica, Ruxandra Dobrescu, Gabriela Anton, Corin Badiu等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

基因解码基因检测的研究介绍：甲状腺癌是全球最常见的内分泌恶性肿瘤。 DNA 甲基化的变化会导致正常活跃基因的沉默，尤其是肿瘤抑制基因 (TSG) 或正常沉默基因的激活。基因解码基因检测的研究目的：本研究的基因解码基因检测的研究目的是评估一组甲状腺肿瘤标志物的启动子甲基化程度和建立它们与甲状腺肿瘤发生的关系。基因解码基因检测的研究方法：为了生成涉及甲状腺肿瘤的 TSG 的全面 DNA 甲基化特征，基因解码基因检测使用 Human TSG EpiTect Methyl II Signature PCR Array-Qiagen 与正常样本相比，对 24 个样本（滤泡性腺瘤和乳头状甲状腺癌）进行了分析。甲状腺组织。基因解码基因检测使用 qMS-PCR 扩展了对三个 TSG（TP73、WIF1、PDLIM4）的评估。使用 GraphPad Prism 进行统计分析。基因解码基因检测的研究结果：基因解码基因检测注意到四个重要基因 NEUROG1、ESR1、RUNX3、MLH1，与正常相比，它们在肿瘤样本中呈现甲基化启动子。基因解码基因检测发现了甲状腺肿瘤的新特征：TP73、WIF1 和 PDLIM4 TSG 的甲基化，这可能导致甲状腺肿瘤。 BRAF V600E突变与RET/PTC重排分别与TIMP3和CDH13、RARB甲基化显着相关。基因解码基因检测的研究结论：TSGs启动子高甲基化是癌症的标志，采用甲基化定量基因解码基因检测的研究方法的检测适用于甲状腺的诊断和预后。癌症。关键词：甲状腺癌；表观遗传学；启动子甲基化；抑癌基因。

肿瘤发生与复发转移国际数据库描述：

Background: Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes.Objective: The aim of this study is to evaluate the degree of promoter methylation for a panel of markers for thyroid neoplasms and to establish their relationship with thyroid oncogenesis.Methods: To generate a comprehensive DNA methylation signature of TSGs involved in thyroid neoplasia, we use Human TSG EpiTect Methyl II Signature PCR Array-Qiagen for 24 samples (follicular adenomas and papillary thyroid carcinomas) compared with normal thyroid tissue. We extended the evaluation for three TSGs (TP73, WIF1, PDLIM4) using qMS-PCR. Statistical analysis was performed with GraphPad Prism.Results: We noted four important genes NEUROG1, ESR1, RUNX3, MLH1, which presented methylated promoter in tumour samples compared to normal. We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia. A significant correlation between BRAF V600E mutation and RET/PTC rearrangements with TIMP3 and CDH13, RARB methylation, respectively was observed.Conclusions: TSGs promoter hypermethylation is a hallmark of cancer and a test that uses methylation quantification method is suitable for diagnosis and prognosis of thyroid cancer.Keywords: Thyroid cancer; epigenetics; promoter methylation; tumour suppressor genes.